Constant rate allocation in nymphal development in species of Hemiptera

Abstract. This study investigated the existence of rate isomorphy (the constant allocation of relative times to different stages of development under different abiotic conditions) in Macrolophus pygmaeus (Hemiptera: Miridae; a phytophagous and predatory insect). Replicated data were used from a range of temperatures regarding (i) the developmental period of each nymphal stage in relation to the total duration of nymph development, when feeding on three host plants either with different prey species or without prey, and (ii) its egg, total nymphal and preoviposition period, on two host plants, with different prey species. The proportion of time required for the development of each nymphal stage of M. pygmaeus is not different among the temperatures or the kind of food available. These proportions ranged among the different host plants, temperatures and prey presence/absence from 17.3–21.8% in the first, 14.5–18.8% in the second, 14.2–18.3% in the third, 16.5–21.0% in the fourth and from 25.4–30.6% in the fifth nymphal stage. Thus, temperature does not significantly affect the proportion of time spent in each nymphal stage and rate isomorphy exists in nymphal development. This phenomenon was also investigated using data from the literature, and it also occurs in several other Hemiptera species. Therefore, there appears to be a constant time allocation in the nymphal development of the higher taxonomic groups of insects. However, for M. pygmaeus, rate isomorphy does not hold when considering egg‐to‐egg development and the relative duration of times to egg hatch, total nymphal development and preoviposition period. The ecophysiological implications of this rate isomorphy phenomenon are discussed in relation to endocrinological mechanisms. Apart from its theoretical interest, the existence of rate isomorphy simplifies studies on the rate of development and the estimation of thermal constants of an insect, which are essential for the prediction of insect population dynamics. It is also proposed that the term ‘rate isomorphy’ does not strictly describe the phenomenon, and it is suggested that ‘constant rate allocation’ would be a more suitable term.     

Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials

ObjectiveType 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD) are closely related, and antidiabetic medications have been shown to be potential therapeutics in NAFLD. Using a network meta-analysis, we sought to examine the effectiveness of antidiabetic agents for the treatment of NAFLD in patients with type 2 diabetes mellitus.MethodsMedline and Embase were searched for randomized controlled trials relating to the use of antidiabetic agents, including sodium-glucose transport protein 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists, and peroxisome proliferator-activated receptor gamma (PPARγ) agonists, biguanides, sulfonylureas and insulin, on NAFLD in patients with diabetes. The p-score was used as a surrogate marker of effectiveness.ResultsA total of 14 articles were included in the analysis. PPARγ agonists were ranked as the best treatment in steatosis reduction, resulting in the greatest reduction of steatosis. There was statistical significance between PPARγ agonists [mean difference (MD): ?6.02%, confidence interval (CI): ?10.37% to ?1.67%] and SGLT2 inhibitors (MD: ?2.60%, CI: ?4.87% to ?0.33%) compared with standard of care for steatosis reduction. Compared with PPARγ agonists, SGLT2 inhibitors resulted in a statistical significant reduction in fibrosis (MD: ?0.06, CI: ?0.10 to ?0.02). Body mass index reduction was highest in SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists. Additionally, SGLT2 inhibitors were ranked as the best treatment for increasing high-density lipoprotein and reducing low-density lipoprotein.ConclusionGlucagon-like peptide-1 receptor agonists and SGLT2 inhibitors were suitable alternatives for the treatment of NAFLD in those with type 2 diabetes mellitus with a reduction in body mass index, fibrosis, and steatosis. SGLT2 inhibitors also have the added benefit of lipid modulation.     

Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals

ObjectiveThe recent introduction of the term metabolic associated fatty liver disease (MAFLD) sought to reclassify nonalcoholic fatty liver disease (NAFLD). MAFLD is thought to improve the encapsulation of metabolic dysregulation. However, recent evidence has found significant differences between MAFLD and NAFLD, and prevailing knowledge has largely arisen from studies on NAFLD. Hence, we conducted a meta-analysis and systematic review of the outcomes associated with MAFLD.MethodsMEDLINE and Embase databases were searched for articles relating to outcomes in MAFLD. Analysis was conducted in random effects with hazard ratios (HRs) to account for longitudinal risk assessment of mortality and systemic complications.ResultsA total of 554 articles were identified, of which 17 articles were included. MAFLD resulted in an increase in the overall mortality (HR, 1.24; confidence interval [CI], 1.13-1.34), cancer-related mortality (HR, 1.27; CI, 1.01-1.54), and cardiovascular disease mortality (HR, 1.28, 1.03-1.53; P = .04) compared with non-MAFLD. MAFLD also increases the risk of cardiovascular events (HR, 1.49; CI, 1.34-1.64; P < .01), stroke (HR, 1.55; CI, 1.37-1.73; P < .01), and chronic kidney disease (HR, 1.53; CI, 1.38-1.68). The presence of MAFLD was also associated with an increased risk of heart failure, obstructive sleep apnea, and malignancy.ConclusionMAFLD can significantly elevate the risk of systemic diseases and mortality. The care of MAFLD thus requires interdisciplinary collaboration, and future clinical trials conducted on MAFLD should aim to reduce the incidence of end-organ damage aside from improving liver histology.